Analysts Set Expectations for VYGR Q1 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Voyager Therapeutics in a research note issued on Tuesday, March 17th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.24) EPS and Q4 2027 earnings at ($0.22) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.

Separately, Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $16.50.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR opened at $3.92 on Wednesday. The company has a market capitalization of $233.63 million, a P/E ratio of -1.93 and a beta of 1.32. The stock’s 50 day moving average price is $3.92 and its 200 day moving average price is $4.19. Voyager Therapeutics has a 52 week low of $2.64 and a 52 week high of $5.55.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC acquired a new position in Voyager Therapeutics during the second quarter valued at approximately $50,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Voyager Therapeutics by 42,410.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 15,729 shares of the company’s stock worth $62,000 after buying an additional 15,692 shares during the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after buying an additional 3,332,544 shares during the period. Altshuler Shaham Ltd bought a new stake in shares of Voyager Therapeutics during the 4th quarter worth $801,000. Finally, Erste Asset Management GmbH grew its stake in Voyager Therapeutics by 7.0% in the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock valued at $4,718,000 after buying an additional 78,348 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Alfred Sandrock sold 14,197 shares of the company’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the sale, the chief executive officer owned 484,060 shares in the company, valued at approximately $1,834,587.40. This represents a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 49,783 shares of company stock worth $188,694. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.